`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`SAMSUNG BIOEPIS CO., LTD.
`Petitioner,
`
`v.
`
`REGENERON PHARMACEUTICALS, INC.
`Patent Owner.
`
`Patent No. 11,253,572
`
`_______________
`
`Inter Partes Review No. IPR2023-00884
`____________________________________________________________
`
`PATENT OWNER’S MOTION FOR PRO HAC VICE ADMISSION OF
`KIRA A. DAVIS UNDER 37 C.F.R. § 42.10(c)
`
`
`
`IPR2023-00884
`
`I.
`
`Relief Requested
`
`Pursuant to 37 C.F.R. § 42.10, Patent Owner Regeneron Pharmaceuticals,
`
`Inc., requests that the Board admit Kira A. Davis pro hac vice in this proceeding.
`
`II.
`
`Statement of Facts Showing Good Cause for the Board to Recognize
`Counsel Pro Hac Vice During the Proceeding
`
`In accordance with 37 C.F.R. § 42.10(c), the Board may recognize counsel
`
`pro hac vice during a proceeding, subject to the conditions set forth therein, and
`
`any others that the Board may impose. Patent Owner sets forth these facts in
`
`support of this motion:
`
`1.
`
`The undersigned contacted counsel for Petitioner (Quinn Emanuel
`
`Urquhart & Sullivan LLP), who indicated that Petitioner did not plan to oppose
`
`Ms. Davis’s admission pro hac vice.
`
`2.
`
`Lead counsel for Patent Owner, Regeneron Pharmaceuticals, Inc.,
`
`Adam Brausa, and Backup counsel, Rebecca Weires are registered practitioners.
`
`3.
`
`Kira A. Davis is an experienced litigator and has established
`
`familiarity with the subject matter at issue in this proceeding. Accompanying this
`
`motion is Exhibit 2060, the Declaration of Kira A. Davis in Support of this Motion
`
`for Admission Pro Hac Vice (“Davis Decl.”). In her declaration, Ms. Davis attests,
`
`among other things, that she is a member in good standing of the bars of the states
`
`of California and New York. Davis Decl. ¶¶ 1-2. Ms. Davis has never been
`
`subject to suspensions or disbarments from practice, nor had applications for
`
`1
`
`
`
`IPR2023-00884
`
`admission to practice denied, nor been subject to any sanctions or contempt
`
`citations by any court or administrative body. Id. ¶¶ 3-5.
`
`4.
`
`Ms. Davis has approximately 12 years of experience litigating patent
`
`cases involving biotechnology. Davis Decl. ¶ 9. As is relevant to this matter,
`
`during the past 12 years, Ms. Davis has litigated a number of cases involving
`
`biologic therapeutics, including fusion proteins and antibodies, as well as cases
`
`relating to methods of treatment using the same. Id. In addition, Ms. Davis’s
`
`familiarity with the subject matter at issue in this proceeding is demonstrated by
`
`her review of the ’572 Patent, all cited prior art, and the IPR petition in this matter.
`
`Davis Decl. ¶ 10.
`
`5.
`
`In her declaration, Ms. Davis also attests to her admission to practice
`
`s§42.10(c) and Unified Patents, Inc. v. Parallel Iron, LLC, IPR2013-00639, Paper
`
`7 (PTAB Oct. 15, 2013). See Davis Decl. ¶¶ 1-10.
`
`III. Conclusion
`
`For the foregoing reasons, Patent Owner respectfully request that the Board
`
`admit Kira A. Davis pro hac vice in this proceeding.
`
`2
`
`
`
`IPR2023-00884
`
`Date: December 21, 2023
`
`Respectfully Submitted,
`
`By: /Adam R. Brausa/
`Adam R. Brausa, Reg. No. 60,287
`MORRISON & FOERSTER LLP
`425 Market Street
`San Francisco, California 94105
`Tel: (415) 268-6053
`ABrausa@mofo.com
`
`Counsel for Patent Owner
`
`3
`
`
`
`IPR2023-00884
`
`Certificate of Service (37 C.F.R. § 42.6(e)(4))
`
`I hereby certify that the attached PATENT OWNER’S MOTION FOR PRO
`
`HAC VICE ADMISSION OF KIRA A. DAVIS UNDER 37 C.F.R. § 42.10(c) and
`
`THE SUPPORTING DECLARATION OF KIRA A. DAVIS, were served on the
`
`date listed below via electronic mail upon the following counsel of record for
`
`Petitioner.
`
`Raymond N. Nimrod (Reg. No. 31,987)
`Matthew A. Traupman (Reg. No. 50,832)
`Landon Andrew Smith (Reg. No. 79,248)
`QUINN EMANUEL URQUHART
`& SULLIVAN, LLP
`51 Madison Ave., 22nd Floor
`New York, NY 10010
`Email: raynimrod@quinnemanuel.com
`Email: matthewtraupman@quinnemanuel.com
`Email: landonsmith@quinnemanuel.com
`Email: qe-samsungbioepis@quinnemanuel.com
`
`Dated: December 21, 2023
`
`/Adam R. Brausa/
`Adam R. Brausa, Reg. No. 60,287
`
`4
`
`